SK285603B6 - Vektor na výrobu IL-4 a muteínov IL-4 v kmeni Escherichia coli, vektor obsahujúci DNA sekvenciu, Escherichia coli transformovaná jedným alebo viacerými vektormi a použitie vektora - Google Patents

Vektor na výrobu IL-4 a muteínov IL-4 v kmeni Escherichia coli, vektor obsahujúci DNA sekvenciu, Escherichia coli transformovaná jedným alebo viacerými vektormi a použitie vektora Download PDF

Info

Publication number: SK285603B6
Authority: SK; Slovakia
Prior art keywords: vector; escherichia coli; muteins; gene; expression
Prior art date: 1999-01-20

Application number

SK76-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK762000A3 (en

Inventor

Heiner Apeler

Hermann Wehlmann

Original Assignee

Bayer Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-20

Filing date

2000-01-19

Publication date

2007-04-05

2000-01-19 Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft

2000-08-14 Publication of SK762000A3 publication Critical patent/SK762000A3/sk

2007-04-05 Publication of SK285603B6 publication Critical patent/SK285603B6/sk

Links

108090000978 Interleukin-4 Proteins 0.000 title claims abstract description 69
239000013598 vector Substances 0.000 title claims abstract description 31
241000588724 Escherichia coli Species 0.000 title claims abstract description 28
238000004519 manufacturing process Methods 0.000 title claims abstract description 9
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 4
108090000623 proteins and genes Proteins 0.000 claims abstract description 38
238000000034 method Methods 0.000 claims abstract description 18
230000027455 binding Effects 0.000 claims abstract description 8
108020004705 Codon Proteins 0.000 claims description 11
230000002103 transcriptional effect Effects 0.000 claims description 7
230000000977 initiatory effect Effects 0.000 claims description 4
238000013519 translation Methods 0.000 claims description 2
241001515965 unidentified phage Species 0.000 claims description 2
238000013518 transcription Methods 0.000 abstract description 6
230000035897 transcription Effects 0.000 abstract description 6
241000701988 Escherichia virus T5 Species 0.000 abstract description 3
108091081024 Start codon Proteins 0.000 abstract 1
102000004388 Interleukin-4 Human genes 0.000 description 55
229940028885 interleukin-4 Drugs 0.000 description 53
239000013612 plasmid Substances 0.000 description 33
230000014509 gene expression Effects 0.000 description 21
230000006698 induction Effects 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 10
108020004414 DNA Proteins 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
230000010076 replication Effects 0.000 description 7
239000013613 expression plasmid Substances 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
229930027917 kanamycin Natural products 0.000 description 6
229960000318 kanamycin Drugs 0.000 description 6
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
229930182823 kanamycin A Natural products 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
101150109249 lacI gene Proteins 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000000539 dimer Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010054278 Lac Repressors Proteins 0.000 description 2
239000001888 Peptone Substances 0.000 description 2
108010080698 Peptones Proteins 0.000 description 2
108091030071 RNAI Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108700005078 Synthetic Genes Proteins 0.000 description 2
239000008272 agar Substances 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
235000019319 peptone Nutrition 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000013112 stability test Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 1
241000908115 Bolivar Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000002278 Ribosomal Proteins Human genes 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
102000055229 human IL4 Human genes 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
101150078341 rop gene Proteins 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
101150006320 trpR gene Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/72—Expression systems using regulatory sequences derived from the lac-operon

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK76-2000A 1999-01-20 2000-01-19 Vektor na výrobu IL-4 a muteínov IL-4 v kmeni Escherichia coli, vektor obsahujúci DNA sekvenciu, Escherichia coli transformovaná jedným alebo viacerými vektormi a použitie vektora SK285603B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99100967A EP1022339B1 (en)	1999-01-20	1999-01-20	Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins

Publications (2)

Publication Number	Publication Date
SK762000A3 SK762000A3 (en)	2000-08-14
SK285603B6 true SK285603B6 (sk)	2007-04-05

Family

ID=8237378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK76-2000A SK285603B6 (sk)	1999-01-20	2000-01-19	Vektor na výrobu IL-4 a muteínov IL-4 v kmeni Escherichia coli, vektor obsahujúci DNA sekvenciu, Escherichia coli transformovaná jedným alebo viacerými vektormi a použitie vektora

Country Status (15)

Country	Link
US (1)	US6506590B1 (cs)
EP (1)	EP1022339B1 (cs)
JP (2)	JP2000210091A (cs)
KR (1)	KR100665148B1 (cs)
AT (1)	ATE334202T1 (cs)
AU (1)	AU772897B2 (cs)
CA (1)	CA2294575C (cs)
CZ (1)	CZ294279B6 (cs)
DE (1)	DE69929638T2 (cs)
DK (1)	DK1022337T3 (cs)
ES (1)	ES2269027T3 (cs)
HU (1)	HU224491B1 (cs)
NO (1)	NO327317B1 (cs)
PT (1)	PT1022337E (cs)
SK (1)	SK285603B6 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10022258A1 (de)	2000-05-08	2001-11-15	Bayer Ag	Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
KR100443570B1 (ko) *	2001-07-31	2004-08-09	크레아젠 주식회사	재조합 인간 인터루킨-4의 제조방법
EP1314739A1 (en)	2001-11-22	2003-05-28	Bayer Ag	Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
JP2006055082A (ja) *	2004-08-20	2006-03-02	National Institute Of Advanced Industrial & Technology	発光甲虫由来赤色発光酵素安定体の生産及び精製法
CN118440969B (zh) *	2024-07-08	2024-10-15	天津凯莱英生物科技有限公司	可溶性表达质粒突变体库的构建方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4689406A (en) *	1983-08-10	1987-08-25	Amgen	Enhancement of microbial expression of polypeptides
HUT43625A (en) *	1986-03-27	1987-11-30	Monsanto Co	Process for increasing yield of proteins with applying new ribosomal binding positions in bacteria
EP0303925B1 (de) *	1987-08-17	1995-06-07	F. Hoffmann-La Roche Ag	Hochreprimierbare Expressionskontrollsequenzen
FR2724665B1 (fr) *	1994-09-16	1996-12-20	Rhone Poulenc Rorer Sa	Procede de production de proteines recombinantes, plasmides et cellules modifiees
MY124565A (en) *	1996-07-19	2006-06-30	Bayer Corp	High-affinity interleukin-4-muteins

1999
- 1999-01-20 DE DE69929638T patent/DE69929638T2/de not_active Expired - Lifetime
- 1999-01-20 EP EP99100967A patent/EP1022339B1/en not_active Expired - Lifetime
2000
- 2000-01-07 ES ES00100129T patent/ES2269027T3/es not_active Expired - Lifetime
- 2000-01-07 PT PT00100129T patent/PT1022337E/pt unknown
- 2000-01-07 AT AT00100129T patent/ATE334202T1/de active
- 2000-01-07 DK DK00100129T patent/DK1022337T3/da active
- 2000-01-14 JP JP2000006477A patent/JP2000210091A/ja active Pending
- 2000-01-14 US US09/483,419 patent/US6506590B1/en not_active Expired - Fee Related
- 2000-01-17 CA CA002294575A patent/CA2294575C/en not_active Expired - Fee Related
- 2000-01-19 CZ CZ2000214A patent/CZ294279B6/cs not_active IP Right Cessation
- 2000-01-19 KR KR1020000002310A patent/KR100665148B1/ko not_active Expired - Fee Related
- 2000-01-19 SK SK76-2000A patent/SK285603B6/sk unknown
- 2000-01-19 NO NO20000262A patent/NO327317B1/no not_active IP Right Cessation
- 2000-01-20 HU HU0000185A patent/HU224491B1/hu not_active IP Right Cessation
- 2000-01-20 AU AU12507/00A patent/AU772897B2/en not_active Ceased
2010
- 2010-08-27 JP JP2010190917A patent/JP2010284174A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69929638D1 (de)	2006-04-13
KR100665148B1 (ko)	2007-01-09
EP1022339B1 (en)	2006-02-01
JP2000210091A (ja)	2000-08-02
CA2294575A1 (en)	2000-07-20
AU772897B2 (en)	2004-05-13
AU1250700A (en)	2000-07-27
PT1022337E (pt)	2006-11-30
CZ2000214A3 (cs)	2000-08-16
ATE334202T1 (de)	2006-08-15
DE69929638T2 (de)	2006-09-21
ES2269027T3 (es)	2007-04-01
KR20000053523A (ko)	2000-08-25
NO20000262D0 (no)	2000-01-19
HUP0000185A2 (en)	2002-09-28
NO20000262L (no)	2000-07-21
JP2010284174A (ja)	2010-12-24
EP1022339A1 (en)	2000-07-26
NO327317B1 (no)	2009-06-08
HU224491B1 (hu)	2005-09-28
HU0000185D0 (en)	2000-04-28
DK1022337T3 (da)	2006-11-06
CA2294575C (en)	2009-04-07
US6506590B1 (en)	2003-01-14
CZ294279B6 (cs)	2004-11-10
SK762000A3 (en)	2000-08-14

Publication	Publication Date	Title
US6291245B1 (en)	2001-09-18	Host-vector system
Martinez et al.	1988	pACYC184-derived cloning vectors containing the multiple cloning site and lacZα reporter gene of pUC8/9 and pUC18/19 plasmids
CA1316850C (en)	1993-04-27	Gram-positive expression control sequences
EP0972838B1 (en)	2004-09-15	Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
Paddon et al.	1987	Expression of Bacillus amyloliquefaciens extracellular ribonuclease (barnase) in Escherichia coli following an inactivating mutation
Altenbuchner et al.	1983	Tn1721-encoded tetracycline resistance: mapping of structural and regulatory genes mediating resistance
US5726039A (en)	1998-03-10	Vectors and transformed host cells for recombinant protein production at reduced temperatures
Stalker et al.	1983	Release of initiation control by a mutational alteration in the R6K pi protein required for plasmid DNA replication.
JP2010284174A (ja)	2010-12-24	プラスミド、それらの構築およびそれらのインターロイキン−４およびインターロイキン−４ムテインの製造における使用
Newman et al.	1979	Evidence for co-transcription of the RNA polymerase genes rpoBC with a ribosomal protein gene of escherichia coli
MXPA04005717A (es)	2005-06-03	Sistema de expresion.
KR100358948B1 (ko)	2002-10-31	인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균
EP1022337B1 (en)	2006-07-26	Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins
Liu et al.	1983	The repA2 gene of the plasmid R100. 1 encodes a represser of plasmid replication
US5654169A (en)	1997-08-05	Vectors and transformed host cells for recombinant protein production at reduced temperatures
WO2000060103A2 (en)	2000-10-12	Dna construct comprising a cyanophage of cyanobacteria promoter and its use
EP2109671B1 (en)	2014-03-26	Expression cassette, use of the expression cassette, vector, host cell, a method for producing a polypeptide
EP0121569B1 (en)	1990-08-22	Novel vector
EP0105554A1 (en)	1984-04-18	DNA and plasmids
Gentschev et al.	1996	Mini-Tn hlyA s: a new tool for the construction of secreted fusion proteins
Bendiak et al.	1977	Fine-structure mapping of the rts, rplK, rplL, and rpoB genes of Escherichia coli
Beck et al.	1980	The tetracycline-resistance transposon Tn10 inhibits translocation of Tn10
EP1461437B1 (en)	2007-11-07	Expression vectors and promoters for heterologous gene expression
Maekawa et al.	1994	Identification of the region that determines the specificity of binding of the transposases encoded by Tn3 and γδ to the terminal inverted repeat sequences
Takebe et al.	1982	In vitro construction of the tufB-lacZ fusion: analysis of the regulatory mechanism of tufB promoter